Immunome: FDA lifts hold on Covid antibody IND

 

• The FDA has lifted the clinical hold on Immunome Inc's 
  IMNM -2.81%
   (Get Free Alerts for IMNM) Investigational New Drug (IND) application for its antibody cocktail (IMM-BCP-01) to treat COVID-19. 
• Immunome previously announced that the FDA had placed its IND application on clinical hold due to a request for further information related to the preparation and administration of IMM-BCP-01 at clinical sites. 
• In response, Immunome provided the FDA with a comprehensive report detailing the necessary information.
• "We believe in the potential of IMM-BCP-01 and its ability to aid in the ongoing fight against SARS-CoV-2, especially as the new variants continue," said Purnanand Sarma, President & CEO of Immunome. "We are pleased to report that the clinical hold has now been lifted. We look forward to advancing the program into the clinic.

https://www.benzinga.com/general/biotech/22/03/26100043/fda-lifts-clinical-hold-on-immunomes-covid-19-candidate-ind